title: Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.
abstract: Disease specific quality of life was measured in the Leeds Multiple Sclerosis (MS) Treatment Programme (n = 210) using the self-report Leeds MS Quality of Life (LMSQoL) scale. The results showed a significant and sustained increase in quality of life associated with 'disease modifying' treatment. This contrasts with the Expanded Disability Status Scores (EDSS), which showed no measurable improvement. An increase in the LMSQoL score did not correlate with baseline age, disease duration, disability or number of prior relapses. There was no significant difference in treatment effect between relapsing-remitting and secondary progressive MS patients, or between patients receiving different products. However, patients with a poor quality of life at baseline showed the most benefit from treatment. Those who had their treatment stopped due to progression, side-effects or lack of effect had significantly lower LMSQoL scores on treatment. In this study, the LMSQoL scale was responsive to change and was easy to administer in a clinical setting.
authors.affiliation: Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK. oliver.lily@leedsth.nhs.uk
authors.forename: O
authors.initials: O
authors.lastname: Lily
authors.forename: E
authors.initials: E
authors.lastname: McFadden
authors.forename: E
authors.initials: E
authors.lastname: Hensor
authors.forename: M
authors.initials: M
authors.lastname: Johnson
authors.forename: H
authors.initials: H
authors.lastname: Ford
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D004185:Disability Evaluation; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000523:psychology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000523:psychology*; D010352:Patient Dropouts; D010455:Peptides / Q000627:therapeutic use; D011788:Quality of Life; D012044:Regression Analysis
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a